EVMN
Evommune Inc. Common Stock (EVMN)
Healthcare • NYSE • $22.92+1.87%
- Symbol
- EVMN
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $22.92
- Daily Change
- +1.87%
- Market Cap
- $825.54M
- Trailing P/E
- N/A
- Forward P/E
- -5.96
- 52W High
- $33.20
- 52W Low
- $13.89
- Analyst Target
- $52.00
- Dividend Yield
- N/A
- Beta
- N/A
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Company websiteResearch EVMN on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.